Original
Beta-Tricalcium Phosphate as a Possible Adjuvant in γδ T Cell-Based Immune Therapy for Human Disorders
2022 年 6 巻 p. 101-107
詳細
2022 年 6 巻 p. 101-107
Objective: γδ T cells can recognize and attack cancer cells even in the absence of information from dendritic cells. γδ T cells have been used in immune cell therapy because of their strong ability to kill cancer cells. However, the number of γδ T cells in peripheral blood is small; therefore, it is important to increase the number of γδ T cells via effective ex vivo culturing.
Methods: In this study, we analyzed the effects of beta-tricalcium phosphate (β-TCP) on γδ T cells derived from peripheral blood.
Results: We confirmed that the number of γδ T cells increased via β-TCP addition to the culture medium in 83.3% of the experiments (5/6 times).
Conclusion: As β-TCP has been widely used in medical therapy, it may be used as a possible adjuvant in γδ T-cell-based immune therapy for human disorders.
